AbbVie jumps into the frenzied race for a BCMA/CD3 bispecific targeting multiple myeloma. Teneobio who?
Everybody wants a BCMA bispecific. And AbbVie just fronted $90 million to get one from a little-known Silicon Valley biotech called Teneobio.
Basic subscription required
Unlock this story instantly and join 53,000+ biopharma pros reading Endpoints daily — and it's free.